| Dose interruptions, reductions, transfusions, and discontinuations . | Talazoparib (N = 61) . |
|---|---|
| Number (%) of patients | n (%) |
| Dose interruptions due to AEs | 20 (32.8) |
| Dose reductions due to AEs | 24 (39.3) |
| Packed red blood cell transfusion | 13 (21.3) |
| Transfusion | 7 (11.5) |
| Permanent drug discontinuation | |
| Adverse event | 3 (4.9) |
| Death | 0 |
| Progressive disease | 10 (16.4) |
| Withdrawal by patienta | 2 (3.3) |
| Otherb | 1 (1.6) |
| Dose interruptions, reductions, transfusions, and discontinuations . | Talazoparib (N = 61) . |
|---|---|
| Number (%) of patients | n (%) |
| Dose interruptions due to AEs | 20 (32.8) |
| Dose reductions due to AEs | 24 (39.3) |
| Packed red blood cell transfusion | 13 (21.3) |
| Transfusion | 7 (11.5) |
| Permanent drug discontinuation | |
| Adverse event | 3 (4.9) |
| Death | 0 |
| Progressive disease | 10 (16.4) |
| Withdrawal by patienta | 2 (3.3) |
| Otherb | 1 (1.6) |
Abbreviations: AE, adverse event; ITT, intent-to-treat.
aOne patient completed only 4 months of treatment and decided to have surgery early and 1 patient withdrew consent from the treatment and also permanently discontinued from the study.
bPatient had surgery early in another country and specimen was not provided to central laboratory.
| Dose interruptions, reductions, transfusions, and discontinuations . | Talazoparib (N = 61) . |
|---|---|
| Number (%) of patients | n (%) |
| Dose interruptions due to AEs | 20 (32.8) |
| Dose reductions due to AEs | 24 (39.3) |
| Packed red blood cell transfusion | 13 (21.3) |
| Transfusion | 7 (11.5) |
| Permanent drug discontinuation | |
| Adverse event | 3 (4.9) |
| Death | 0 |
| Progressive disease | 10 (16.4) |
| Withdrawal by patienta | 2 (3.3) |
| Otherb | 1 (1.6) |
| Dose interruptions, reductions, transfusions, and discontinuations . | Talazoparib (N = 61) . |
|---|---|
| Number (%) of patients | n (%) |
| Dose interruptions due to AEs | 20 (32.8) |
| Dose reductions due to AEs | 24 (39.3) |
| Packed red blood cell transfusion | 13 (21.3) |
| Transfusion | 7 (11.5) |
| Permanent drug discontinuation | |
| Adverse event | 3 (4.9) |
| Death | 0 |
| Progressive disease | 10 (16.4) |
| Withdrawal by patienta | 2 (3.3) |
| Otherb | 1 (1.6) |
Abbreviations: AE, adverse event; ITT, intent-to-treat.
aOne patient completed only 4 months of treatment and decided to have surgery early and 1 patient withdrew consent from the treatment and also permanently discontinued from the study.
bPatient had surgery early in another country and specimen was not provided to central laboratory.
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
